Nektar Therapeutics (NKTR) Current Deferred Revenue (2010 - 2020)

Nektar Therapeutics' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $2.6 million for Q4 2020.

• In Q4 2020, Current Deferred Revenue fell 68.34% year-over-year to $2.6 million; the TTM figure through Dec 2020 stood at $2.6 million (down 68.34% YoY), while the FY2020 annual figure was $2.6 million, down 68.34% from the prior year.
• Current Deferred Revenue was $2.6 million for Q4 2020 at Nektar Therapeutics, up from $507000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $38.0 million in Q4 2017 to a low of $507000.0 in Q3 2020.
• Historically, Current Deferred Revenue has averaged $15.2 million across 5 years, with a median of $14.2 million in 2016.
• The sharpest annual moves came in 2017 and 2020: Current Deferred Revenue surged 164.56% in 2017, then slumped 93.96% in 2020.
• A 5-year view of Current Deferred Revenue shows it stood at $14.4 million in 2016, then soared by 164.56% to $38.0 million in 2017, then sank by 35.12% to $24.6 million in 2018, then slumped by 67.24% to $8.1 million in 2019, then tumbled by 68.34% to $2.6 million in 2020.
• The last three Current Deferred Revenue figures came in at $2.6 million (Q4 2020), $507000.0 (Q3 2020), and $4.3 million (Q2 2020), per Business Quant data.